Reducing reductionism: addressing risk for atherosclerotic cardiovascular disease by apolipoprotein proteomics

Eur Heart J. 2023 Jul 14;44(27):2420-2422. doi: 10.1093/eurheartj/ehad294.

Authors

Lukas E Schmidt¹, Walter S Speidl¹, Sotirios Tsimikas², Manuel Mayr^{1

3}

Affiliations

¹ Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Vienna, Austria.
² Sulpizio Cardiovascular Center, Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA.
³ King's British Heart Foundation Centre, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, 125 Coldharbour Lane, London SE5 9NU, Greater London, UK.

PMID: 37264561
DOI: 10.1093/eurheartj/ehad294

No abstract available

MeSH terms

Apolipoproteins
Atherosclerosis* / prevention & control
Cardiovascular Diseases* / prevention & control
Humans
Proteomics

Substances

Apolipoproteins

Grants and funding